- Home
- AZ vs ZNTL Comparison
AZ vs ZNTL Comparison
Compare AZ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | ZNTL |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 289.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AZ | ZNTL |
|---|---|---|
| Price | $6.14 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $22.50 | $7.33 |
| AVG Volume (30 Days) | 394.5K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $350.76 | N/A |
| Revenue Next Year | $206.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.97 | $1.25 |
| 52 Week High | $8.73 | $6.95 |
Technical Indicators
Market Signals| Indicator | AZ | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 29.38 |
| Support Level | $5.19 | N/A |
| Resistance Level | $6.27 | $2.76 |
| Average True Range (ATR) | 0.33 | 0.17 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 51.85 | 17.26 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.